Antiphospholipid Syndrome: Blood Clots, Pregnancy Loss, and Autoimmune Testing

When a Clot Is Also an Autoimmune Signal

Antiphospholipid syndrome (APS) matters because its first clue is often a consequential event: a deep vein thrombosis in a young adult, a stroke without typical vascular risk factors, or recurrent pregnancy loss after otherwise reassuring evaluations. For patients, APS can make a blood clot feel less random. For clinicians, it changes how we interpret thrombosis, miscarriage, lupus activity, and anticoagulation choices.

APS is not simply “thick blood.” It is an acquired autoimmune disorder in which persistent antiphospholipid antibodies increase thrombin generation, activate endothelial cells and platelets, and disturb placental development. The practical question is therefore not only whether a clot occurred, but whether the immune system created a durable risk pattern that requires a different long-term plan.

What APS Antibodies Mean, and What They Do Not

The updated 2023 ACR/EULAR classification criteria emphasize two domains: clinical events, such as vascular thrombosis or specific pregnancy complications, and laboratory evidence of persistent antiphospholipid antibodies. Classification criteria are designed for research cohorts, not bedside diagnosis, but they capture a central principle: APS requires both a compatible clinical story and reproducible antibody positivity.

The three standard tests are lupus anticoagulant, anticardiolipin IgG or IgM, and anti-beta-2 glycoprotein I IgG or IgM. Despite the name, lupus anticoagulant is associated with clotting in the body, not bleeding. It can also be distorted by anticoagulant medications, acute illness, and laboratory technique, which is why repeat testing at least 12 weeks later is essential.

Blood Clots: Why the Pattern Matters

APS can cause venous events, including deep vein thrombosis and pulmonary embolism, and arterial events, including ischemic stroke or myocardial infarction. Arterial APS is especially important because it often pushes clinicians away from assuming conventional atherosclerosis is the whole explanation, particularly in younger patients or those with systemic lupus erythematosus (SLE).

Risk is not uniform. “Triple positive” patients, meaning all three antibody categories are positive, have the highest recurrence risk. Lupus anticoagulant generally carries more thrombotic weight than isolated low-level anticardiolipin IgM. That distinction is clinically decisive because treatment intensity, medication selection, and the threshold for indefinite anticoagulation depend on the pretest probability and antibody profile.

Consider a 36-year-old woman with SLE who develops an unprovoked leg clot. If she has persistent lupus anticoagulant, high-titer anticardiolipin IgG, and anti-beta-2 glycoprotein I IgG, the episode is interpreted differently than a clot after major surgery with one borderline antibody. The first scenario suggests a durable autoimmune prothrombotic state; the second may not.

Pregnancy Loss and Placental APS

Obstetric APS is not just recurrent miscarriage. It can present as fetal death after 10 weeks, premature birth because of severe preeclampsia or placental insufficiency, or recurrent early pregnancy losses. The unifying biology is impaired placentation, complement activation, and local clotting or inflammation at the maternal-fetal interface.

EULAR recommendations support low-dose aspirin plus prophylactic heparin during pregnancy for many patients with obstetric APS, with escalation in selected refractory cases. Warfarin is avoided during most of pregnancy because of fetal risk, but it remains central for many nonpregnant patients with thrombotic APS. This illustrates an APS theme: the same antibody profile may require different strategies depending on pregnancy, clot type, bleeding risk, and prior events.

Treatment Reasoning: Anticoagulation Is Not One-Size-Fits-All

For thrombotic APS, vitamin K antagonists such as warfarin remain the best-supported long-term therapy. The TRAPS trial, which enrolled high-risk triple-positive APS patients, found more recurrent events with rivaroxaban than warfarin, especially arterial events. Subsequent guidance from EULAR and other societies generally discourages direct oral anticoagulants in high-risk APS, particularly triple-positive or arterial disease.

That does not mean every positive antiphospholipid antibody mandates lifelong warfarin. Clinicians weigh whether the clot was provoked, whether antibodies are persistent and high risk, whether SLE or cardiovascular risk factors are present, and whether bleeding risk alters the equation. Aspirin may be considered for selected high-risk antibody-positive patients without prior thrombosis, but evidence is less definitive than for secondary prevention after a clot.

Testing Pitfalls That Change Management

The most common misconception is that APS can be ruled in or out with one laboratory draw. It cannot. Testing during an acute clot, while hospitalized, or while taking heparin, warfarin, or a direct oral anticoagulant can produce misleading lupus anticoagulant results. Repeat testing after 12 weeks, coordinated with the treating team, is not bureaucracy; it separates persistent autoimmunity from noise.

A practical testing frame

• Test when the result would change management, such as unprovoked thrombosis, arterial thrombosis in a young patient, recurrent pregnancy loss, or suggestive SLE features.
• Confirm persistence at least 12 weeks later using the same antibody categories, and interpret titers and lupus anticoagulant status together.
• Do not treat the laboratory report in isolation; integrate age, provoking factors, medications, pregnancy plans, renal disease, and bleeding risk.

Where the Evidence Stands

Current evidence supports a disciplined approach: diagnose APS only when clinical events and persistent antibodies align; identify high-risk profiles, especially lupus anticoagulant and triple positivity; use warfarin rather than direct oral anticoagulants for most high-risk thrombotic APS; and treat obstetric APS with pregnancy-specific anticoagulation strategies. Uncertainty remains around primary prevention for asymptomatic antibody-positive patients, optimal intensity after arterial thrombosis, and management of refractory pregnancy complications despite aspirin and heparin. The field is moving toward better risk stratification, including complement biology and noncriteria antibodies, but today the most important intervention is careful interpretation. In APS, the right diagnosis is not a label; it is the foundation for preventing events that are often life changing for patients, clinicians, and families.